The first bevacizumab biosimilar in China was approved for marketing

　　CCTV News:Recently, the State Drug Administration approved the application for marketing registration of bevacizumab injection developed by Qilu Pharmaceutical Co., Ltd. The drug is the first bevacizumab biosimilar approved in China, which is mainly used for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer.

　　Bevacizumab is a humanized monoclonal antibody IgG1 prepared by recombinant DNA technology. It binds to human vascular endothelial growth factor (VEGF), inhibits the binding of VEGF to its receptor, blocks the signal transduction pathway of angiogenesis, and inhibits the growth of tumor cells. As one of the important drugs against tumor angiogenesis, bevacizumab is used in the treatment of various malignancies.

　　The approved bevacizumab injection was declared by the pharmaceutical industry. It is the first product in China to use the original bevacizumab as a reference drug and develop and declare production according to the biosimilar route. It has received the support of the national major new drug creation special project. The State Food and Drug Administration approved the listing of this variety according to the priority review and approval procedure. The approval of this product will improve the accessibility of this type of drug and provide new options for the treatment of domestic patients.